Discover J&J’s pipeline strategy for 2026 as it it projects that its sales for the year will be between $100 billion and $101 ...
Sagimet Biosciences dropped 9% after Ascletis Pharma’s Phase 3 Denifanstat safety data focused on tolerability, not new ...
TECH is set to report Q2 results on Feb. 4, with EPS seen at 43 cents and revenues at $292M as tariffs, NIH funding and segment shifts shape outlook.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results